BridgeBio Pharma

US · BBIO #1254 by market cap Listed 2019

66.50 -0.46 -0.69%

Live - 5344 symbols - heartbeat 288s ago · 2026-10-08 05:32

Pre-market 66.30 -0.30%

After-hours 65.99 -0.77%

Overnight 66.50 0.00%

Market cap: 13.00B
P/E (TTM): -18.68
P/B: -5.17
EPS: -3.78
Div yield: 0.00%
52W pos: 34%

Reader sentiment Are you bullish or bearish on BBIO?

Anonymous reader poll. Unscientific, not investment advice.

About BridgeBio Pharma

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Founded: 2015
CEO: Dr. Neil Kumar, PhD
Employees: 839
Headquarters: Palo Alto, California, United States of America
Fiscal year end: 12-31
Website: bridgebio.com

Company profile

Exchange: US
Symbol: BBIO
Market-cap rank: #1254
Listing date: 2019-06-27
Market cap: 13.00B
Float cap: 11.12B
Shares out: 195.49M
Float shares: 167.20M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 05:32:13 · For reference only, not investment advice and not tailored to your situation.